Uno studio randomizzato di Fase III sull'adiuvante Dato-DXd in combinazione con Rilvegostomig o Rilvegostomig in monoterapia rispetto allo standard di cura, dopo resezione completa del tumore, in partecipanti con adenocarcinoma NSCLC in stadio I che sono ctDNA-positivi o presentano caratteristiche patologiche ad alto rischio (TROPION-Lung12)
Uno studio globale di Fase III, randomizzato, in aperto, sull'adiuvante Datopotamab Deruxtecan (Dato-DXd) in combinazione con Rilvegostomig o Rilvegostomig in monoterapia rispetto allo standard di cura, dopo resezione completa del tumore, in partecipanti con adenocarcinoma in stadio I e carcinoma polmonare non a piccole cellule Chi è ctDNA-positivo o presenta caratteristiche patologiche ad alto rischio (TROPION-Lung12)
This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The primary objective of the study is to assess the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig relative to SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Barretos, Brasile, 14784-057
- Research Site
-
Brasília, Brasile, 70200-730
- Research Site
-
Florianópolis, Brasile, 88034-000
- Research Site
-
São Paulo, Brasile, 01323-903
- Research Site
-
Teresina, Brasile, 64049-200
- Research Site
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Research Site
-
-
Ontario
-
Oshawa, Ontario, Canada, L1G 2B9
- Research Site
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 3J4
- Research Site
-
-
-
-
-
Bunkyō City, Giappone, 113-8603
- Research Site
-
Chiba, Giappone, 260-0877
- Research Site
-
Chūōku, Giappone, 104-0045
- Research Site
-
Fukuoka, Giappone, 812-8582
- Research Site
-
Hidaka-shi, Giappone, 350-1298
- Research Site
-
Hiroshima, Giappone, 734-8551
- Research Site
-
Hiroshima, Giappone, 730-8518
- Research Site
-
Iwakuni-shi, Giappone, 740-8510
- Research Site
-
Kashiwa, Giappone, 277-8577
- Research Site
-
Kitaadachi-gun, Giappone, 362-0806
- Research Site
-
Kobe, Giappone, 650-0017
- Research Site
-
Kumamoto, Giappone, 860-8556
- Research Site
-
Kōtoku, Giappone, 135-8550
- Research Site
-
Nagoya, Giappone, 464-8681
- Research Site
-
Niigata, Giappone, 951-8566
- Research Site
-
Osakasayama-shi, Giappone, 589-8511
- Research Site
-
Sapporo, Giappone, 003-0804
- Research Site
-
Sendai, Giappone, 980-8574
- Research Site
-
Sendai, Giappone, 980-0873
- Research Site
-
Wakayama, Giappone, 641-8510
- Research Site
-
Yokohama, Giappone, 241-8515
- Research Site
-
-
-
-
-
Hong Kong, Hong Kong, 999077
- Research Site
-
-
-
-
-
Kuala Lumpur, Malaysia, 59100
- Research Site
-
Kuala Lumpur, Malaysia, 50586
- Research Site
-
Kuching, Malaysia, 93586
- Research Site
-
-
-
-
Arizona
-
Tucson, Arizona, Stati Uniti, 85724
- Research Site
-
-
California
-
Duarte, California, Stati Uniti, 91010
- Research Site
-
Glendale, California, Stati Uniti, 91204
- Research Site
-
Los Angeles, California, Stati Uniti, 90089
- Research Site
-
-
Colorado
-
Lone Tree, Colorado, Stati Uniti, 80124
- Research Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20007
- Research Site
-
-
Florida
-
Jacksonville, Florida, Stati Uniti, 32224
- Research Site
-
St. Petersburg, Florida, Stati Uniti, 33709
- Research Site
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60637
- Research Site
-
Evanston, Illinois, Stati Uniti, 60201
- Research Site
-
Zion, Illinois, Stati Uniti, 60099
- Research Site
-
-
Kansas
-
Kansas City, Kansas, Stati Uniti, 66160
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40503
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21237
- Research Site
-
-
Michigan
-
Farmington Hills, Michigan, Stati Uniti, 48334
- Research Site
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Research Site
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55407
- Research Site
-
-
Montana
-
Billings, Montana, Stati Uniti, 59102
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti, 68130
- Research Site
-
-
New York
-
East Syracuse, New York, Stati Uniti, 13057
- Research Site
-
Mineola, New York, Stati Uniti, 11501
- Research Site
-
New York, New York, Stati Uniti, 10016
- Research Site
-
New York, New York, Stati Uniti, 10065
- Research Site
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97239
- Research Site
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Stati Uniti, 18015
- Research Site
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Research Site
-
Pittsburgh, Pennsylvania, Stati Uniti, 15212
- Research Site
-
-
Tennessee
-
Knoxville, Tennessee, Stati Uniti, 37920
- Research Site
-
Memphis, Tennessee, Stati Uniti, 38120
- Research Site
-
Nashville, Tennessee, Stati Uniti, 37203
- Research Site
-
-
Texas
-
Austin, Texas, Stati Uniti, 78745
- Research Site
-
Dallas, Texas, Stati Uniti, 75231
- Research Site
-
Houston, Texas, Stati Uniti, 77030
- Research Site
-
San Antonio, Texas, Stati Uniti, 78217
- Research Site
-
-
Virginia
-
Fairfax, Virginia, Stati Uniti, 22031
- Research Site
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98104
- Research Site
-
-
Wisconsin
-
Madison, Wisconsin, Stati Uniti, 53792
- Research Site
-
-
-
-
-
Bangkok, Tailandia, 10400
- Research Site
-
Bangkoknoi, Tailandia, 10700
- Research Site
-
Banphaeo, Tailandia, 74120
- Research Site
-
Dusit, Tailandia, 10300
- Research Site
-
Hat Yai, Tailandia, 90110
- Research Site
-
Muang, Tailandia, 50200
- Research Site
-
Muang, Tailandia, 40002
- Research Site
-
Ratchathewi, Tailandia, 10400
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwan, 80756
- Research Site
-
Taipei, Taiwan, 10002
- Research Site
-
Taipei, Taiwan, 112
- Research Site
-
Taipei, Taiwan, 114
- Research Site
-
Taoyuan, Taiwan, 333
- Research Site
-
-
-
-
-
Ankara, Turchia (Türkiye), 06280
- Research Site
-
Ankara, Turchia (Türkiye), 06010
- Research Site
-
Mersin, Turchia (Türkiye), 33240
- Research Site
-
-
-
-
-
Hanoi, Vietnam, 100000
- Research Site
-
Ho Chi Minh City, Vietnam, 700000
- Research Site
-
Hà Nội, Vietnam, 100000
- Research Site
-
Vinh, Vietnam, 460000
- Research Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Histologically documented treatment-naive Stage I (T < 4 cm, AJCC 8th ed) adenocarcinoma NSCLC
- Complete surgical resection (R0) of the primary NSCLC
- Unequivocal no evidence of disease at post-surgical
- Pre-surgical ctDNA-positive result (Stage IA or IB) OR presence of at least one high-risk pathological feature (visceral pleural invasion (VPI), lymphovascular invasion (LVI), high-grade histology) (Stage IB only)
- ECOG of 0 or 1, life expectancy of > 6 months and complete recovery after surgery
- Adequate bone marrow reserve and organ function
Exclusion Criteria:
- Sensitizing EGFR mutation and/or ALK alteration
- History of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
- Significant pulmonary function compromise
- History of another primary malignancy within 3 years (with exceptions)
- Any evidence of severe or uncontrolled systemic diseases, including but not limited to bleeding diseases, active infection and cardiac disease
- Active or prior documented autoimmune or inflammatory disorders (with exceptions)
- Active infection with tuberculosis, hepatitis B or C virus, hepatitis A, or known HIV infection that is not well controlled
- History of active primary immunodeficiency
- Clinically significant corneal disease
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Dato-DXd + rilvegostomig
Participants in the Dato-DXd in combination with rilvegostomig group will receive Dato-DXd and rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W). |
Datopotamab Deruxtecan IV (intravenous)
Altri nomi:
Rilvegostomig IV (intravenous)
Altri nomi:
|
|
Sperimentale: Rilvegostomig
Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W). |
Rilvegostomig IV (intravenous)
Altri nomi:
|
|
Comparatore attivo: Standard of Care (SoC)
Patients in SoC group will undergo observation or will receive Investigator's Choice of Chemotherapy (ICC). |
Carboplatin IV (intravenous), Active Comparator Cisplatin IV (intravenous), Active Comparator Etoposide IV (intravenous), Active Comparator Pemetrexed IV (intravenous), Active Comparator Vinorelbine IV (intravenous), Active Comparator UFT Oral route of administration, Active Comparator |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Disease-Free Survival (DFS) using BICR in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
Lasso di tempo: From date of randomisation up to approximately 10 years.
|
The analysis will include all randomised participants as randomised. All events will be included, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy. The measure of interest is the HR of DFS. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
From date of randomisation up to approximately 10 years.
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall Survival (OS) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
Lasso di tempo: From date of randomisation up to approximately 10 years.
|
The analysis will include all randomised participants as randomised. All deaths will be included, regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy. The measure of interest is the HR of OS. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
From date of randomisation up to approximately 10 years.
|
|
Participant-reported physical function in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
Lasso di tempo: Measured at weeks 12, 24 and 48.
|
The analysis will include all randomised participants as randomised. The physical function will be measured by the PROMIS SF PF 8c. Data from PROMIS SF PF 8c will capture participants' perceived ability to perform specific activities from daily life and will be scored on a 5-point rating scale. The measure of interest will be the between treatment group difference in adjusted mean in physical function scores. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
Measured at weeks 12, 24 and 48.
|
|
Participant-reported GHS/QoL in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive or having at least one high-risk pathological feature treated with adjuvant Dato-DXd in combination with rilvegostomig relative to SoC
Lasso di tempo: Measured at weeks 12, 24 and 48.
|
The analysis will include all randomised participants as randomised. The GHS/QoL scores will be measured by the GHS/QoL scale from EORTC IL172. The measure of interest will be the between treatment group difference in adjusted mean in GHS/QoL scores. Descriptive analyses of Dato-DXd in combination with rilvegostomig versus rilvegostomig monotherapy and rilvegostomig monotherapy versus SoC will be performed to assess contribution of components. |
Measured at weeks 12, 24 and 48.
|
|
Pharmacokinetics (PK)
Lasso di tempo: Up to 30 or 90 days post-last dose of study intervention.
|
Concentration of Dato-DXd, total anti-TROP2 antibody, and MAAA-1181a (payload deruxtecan) in plasma or serum. |
Up to 30 or 90 days post-last dose of study intervention.
|
|
Pharmacokinetics (PK)
Lasso di tempo: Up to 30 or 90 days post-last dose of study intervention.
|
Concentration of rilvegostomig in plasma or serum. |
Up to 30 or 90 days post-last dose of study intervention.
|
|
Pharmacokinetics (PK)
Lasso di tempo: Up to 30 or 90 days post-last dose of study intervention.
|
PK parameters (peak and through concentrations). |
Up to 30 or 90 days post-last dose of study intervention.
|
|
Immunogenicity
Lasso di tempo: Up to 30 or 90 days post-last dose of study intervention.
|
Presence of ADAs for Dato-DXd and rilvegostomig (confirmatory results: titres and neutralising antibodies for confirmed positive samples). |
Up to 30 or 90 days post-last dose of study intervention.
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: David Jones, MD, Memorial Sloan Kettering Cancer Center, New York, United States of America
- Investigatore principale: Enriqueta Felip, MD, Vall d'Hebron Hospital, Barcelona, Spain
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Malattie delle vie respiratorie
- Neoplasie per tipo istologico
- Malattie polmonari
- Neoplasie, ghiandolari ed epiteliali
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Neoplasie polmonari
- Carcinoma
- Carcinoma, broncogeno
- Neoplasie bronchiali
- Carcinoma, polmone non a piccole cellule
- Adenocarcinoma
- Aminoacidi, peptidi e proteine
- Prodotti chimici organici
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Idrocarburi
- Idrocarburi, ciclici
- Carboidrati
- Alcaloidi
- Podofillotossina
- Tetraidonaftalene
- Naftalene
- Idrocarburi policiclici aromatici
- Idrocarburi, aromatici
- Composti policiclici
- Glucosidi
- Glicosidi
- Indoli
- Prodotti chimici inorganici
- Composti di cloro
- Composti di azoto
- Complessi di coordinamento
- Guanina
- Ipossantine
- Purinoni
- Purine
- Glutammati
- Aminoacidi, acido
- Aminoacidi
- Aminoacidi, dicarbossilico
- Vinca Alkaloids
- Alcaloidi di triptamina di secologia
- Alcaloidi indolo
- Indolizidine
- Indolizine
- Composti di platino
- Vinorelbina
- Pemetrexed
- Etoposide
- Carboplatino
- Cisplatino
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- D926TC00001
- 2024-512195-35-00 (Identificatore di registro: CTIS)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Periodo di condivisione IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Criteri di accesso alla condivisione IPD
When a request has been approved, AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool.
Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .